Results 171 to 180 of about 2,761 (203)
Some of the next articles are maybe not open access.
Citicoline in the treatment of Parkinson's disease.
Clinical therapeutics, 1991The subjects were 20 patients with Parkinson's disease. They were aged 52 to 76 years and the duration of the disease ranged from four to 25 years (mean, 12.5 years). All the patients were receiving levodopa alone or in combination with tricyclic antidepressants, amantadine, bromocriptine, anticholinergic agents, or lisuride.
J F, Martà Massó, M, Urtasun
openaire +3 more sources
Citicoline. Ferrer Internacional.
Current opinion in investigational drugs (London, England : 2000), 2002Citicoline was originally developed and launched by Ferrer for the treatment of stroke, and is now also being investigated for the potential treatment of Alzheimer's disease (AD). In the US, the compound is being developed by Interneuron for the treatment of stroke.
openaire +1 more source
Citicoline as Adjuvant Therapy in Parkinson's Disease: A Systematic Review
Clinical Therapeutics, 2021Roland Dominic Jamora
exaly
Recombinant microorganism for producing citicoline and method for producing citicoline
2023JIANG JUNJUN +5 more
openaire +1 more source
Neuroprotective Effects of Citicoline in in Vitro Models of Retinal Neurodegeneration
International Journal of Molecular Sciences, 2014Fiorella Malchiodi-albedi +2 more
exaly